Skip to content
OpenCapital
Get started

Nuvalent, Inc. NUVL NVL-330 — Direct Expenses Related To Program

Similar metrics at other companies

Praxis Precision Medicines, Inc. logo
PRAXVormatrigine — Program-specific expenses
$20.49M+49.2%
Praxis Precision Medicines, Inc. logo
PRAXRelutrigine — Program-specific expenses
$12.85M+139%
TRA
TRAXPreclinical And Other Unallocated Costs — Research And Development Expense Reversal Excluding Acquired In Process Cost
$3.3M-16.2%
Bristol-Myers Squibb logo
BMYR&D
$2.65B+17.4%
Axsome Therapeutics logo
AXSMAZD7325 — Research And Development Expense
$2.3M—
Royalty Pharma logo
RPRXPhase 2b, TEV-408 — Research and development funding expense
$14.3M—

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept nuvl:DirectExpensesRelatedToProgram.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s nvl-330 — direct expenses related to program.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s NVL-330 — direct expenses related to program?
Nuvalent, Inc. (NUVL) reported NVL-330 — direct expenses related to program of $6.83M in Q1 2026.
How has Nuvalent, Inc.'s NVL-330 — direct expenses related to program changed year-over-year?
Nuvalent, Inc.'s NVL-330 — direct expenses related to program increased by 72.3% year-over-year, from $3.96M to $6.83M.
What is the long-term trend for Nuvalent, Inc.'s NVL-330 — direct expenses related to program?
Over 2 years (2023 to 2025), Nuvalent, Inc.'s NVL-330 — direct expenses related to program has grown at a 43.2% compound annual growth rate (CAGR), from $10.63M to $21.82M.
What does NVL-330 — direct expenses related to program mean?
This metric represents the aggregate direct research and development costs specifically attributable to the advancement of a single clinical-stage drug candidate. It encompasses expenses such as clinical trial site operations, manufacturing of investigational product, and specialized laboratory testing required for regulatory progression. Tracking these costs allows stakeholders to evaluate the capital intensity and resource allocation efficiency of individual pipeline assets.